We will soon close another round of successful investment in our flagship HMRC approved, Human Health EIS KI Fund. The final date to receive cleared funds is the 31st October 2021.

Below is a flavour of some of the companies that you could be investing into.

AlternOx – Biotech – Anti Fungal
A spin-out of the University of Sussex focused on the exploitation of novel and proprietary inhibitors of the enzyme alternative oxidase (AOX) to treat a wide range of multi-drug and multi compound resistant species of fungi that now threaten human health and food security worldwide.

In4Derm – Biotech – Inflammation and Oncology
A spinout from Dundee University. In4Derm is an innovative drug discovery company that develops the next generation of topical and oral therapies for widespread inflammatory conditions, such as eczema or rheumatoid arthritis. Recently, In4Derm announced a Strategic Partnership with a Nasdaq listed biotech with a >$200m Option License Agreement.

Neurocentrx – Biotech – Neuro
Neurocentrx Pharma, a Scotland UK based company, has developed oral ketamine formulations, Keticap™ IR (immediate release) and Keticap™ AD (abuse-deterrent) intended to treat mood disorders like Depression, more effectively.

Oxford Drug Design – Biotech – Machine learning platform to support drug design

Spun out from Professor Graham Richards’ group at the University of Oxford. The company has developed rapid, state-of-the-art virtual screening and ligand analogue searching technologies. Building on this platform, the company is now applying machine learning techniques such as neural networks and topological data analysis to help further the drug discovery process.

Spirea – Biotech – ADC

Spirea, a biotech company spun out from the University of Cambridge, is committed to delivering the next generation of antibody-drug conjugate (ADC) therapeutics to revolutionise cancer treatment and improve the lives of patients.

Stingray Therapeutics – Biotech – Oncology

Stingray Therapeutics is a spin out from the University of Sussex, building on innovative science to generate novel therapies to help improve the quality of life for estrogen sensitive breast cancer patients and potentially other cancer indications.

There are Significant Tax Benefits When Investing into a KI Fund*:

• Investing in a Knowledge-intensive EIS fund provides greater predictability for your tax planning.
• If you invest in a KI approved EIS fund, the investment date for income tax purposes is the date the fund closes. In other words, you know at the point of investment that you should be able to use the income tax relief in the tax year in which you invest or carry back to the previous tax year – effectively getting back tax you’ve already paid.
• In addition, investors can claim tax relief on up to £2m per annum, if at least £1m of this is invested in the knowledge intensive companies.
• Simplified paperwork, you receive a single EIS5 Certificate for your investment rather than the typical 10–15 separate EIS3 certificates.

o2h ChaiTime on Biotech and IPOs: 

Continuing our ChaiTime webinars, last week we had a discussion around ‘Biotech’s and IPO’s. Three of the panelists were CEO’s of existing portfolio companies that have recently been listed. You can see the recording on our YouTube channel Season 3 Ep 3 Recording

We hope that you enjoy the ChaiTime recording and we also look forward to welcoming you into our o2h Ventures fund in which we seek to invest into the best of British science and have a significant impact on the treatment of human diseases.